

**Draft January 19, 2025**

**MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)**

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

February 26-28, 2025

**Wednesday, February 26, 2025**

**8:00 Welcome & Introductions**

Dr. Keipp Talbot (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

**8:30 Meningococcal Vaccines**

Introduction  
GSK Pentavalent Vaccine: Review of EtR and Work Group Considerations  
Updates to Meningococcal Vaccines VFC Resolution  
Introduction to MenQuadfi Label Change for Infants  
MenQuadfi in Infants: Safety and Immunogenicity  
Work Group Considerations regarding MenQuadfi in Infants

Dr. Jamie Loehr (ACIP, WG Chair)  
Dr. Sarah Schillie (CDC/NCIRD)  
  
Dr. Jeanne Santoli (CDC/NCIRD)  
Dr. Sarah Schillie (CDC/NCIRD)  
Dr. Rachel Dawson (Sanofi)  
Dr. Sarah Schillie (CDC/NCIRD)

**9:45 Break**

**10:00 Chikungunya Vaccines**

Introduction  
Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers  
EtR for use of virus-like particle chikungunya vaccine among adolescent and adult travelers  
EtR for use of virus-like particle chikungunya vaccine among laboratory workers  
Clinical guidance for use of virus-like particle chikungunya vaccine among pregnant and breastfeeding women

Dr. Edwin Asturias (ACIP/WG Chair)  
Dr. Susan Hills (CDC/NCEZID) and TBD  
Dr. Susan Hills (CDC/NCEZID)  
Dr. Susan Hills (CDC/NCEZID)  
Dr. Susan Hills (CDC/NCEZID) and TBD

**12:30 Break**

**1:10 Influenza Vaccines**

Introduction  
Influenza Vaccine Effectiveness Update  
FluMist Self or Caregiver Administration  
LAIV for people with asthma  
Influenza Vaccines VFC Resolution

Dr. Jamie Loehr (ACIP, WG Chair)  
TBD  
TBD  
TBD  
Dr. Jeanne Santoli (CDC/NCIRD)

**3:10 Break**

**3:20 Public Comment**

**3:40 VOTES**

Meningococcal Vaccines  
Meningococcal Vaccines VFC  
Chikungunya Vaccines  
Influenza Vaccines  
Influenza Vaccines VFC

Dr. Sarah Schillie (CDC/NCIRD)  
Dr. Jeanne Santoli (CDC/NCIRD)  
Dr. Susan Hills (CDC/NCEZID)  
Dr. Lisa Grohskopf (CDC/NCIRD)  
Dr. Jeanne Santoli (CDC/NCIRD)

**4:10 Break**

**4:20 Respiratory Syncytial Virus (RSV) Vaccines - Maternal/Pediatric**

Introduction  
Evidence to Recommendations: Clesrovimab  
Clinical Considerations

Dr. Helen Chu (ACIP, WG Chair)  
Ms. Danielle Moulia (CDC/NCIRD)  
Dr. Jefferson Jones (CDC/NCIRD)

**5:20 Recess**

**Thursday, February 27, 2025**

<b>8:00 Welcome &amp; Introductions</b>		Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) (CDC, CMS, FDA, HRSA, IHS, OIDP, NIH)
<b>8:10 Agency Updates</b>		
<b>8:30 Respiratory Syncytial Virus (RSV) Vaccines - Adults</b>		
Introduction		Dr. Albert Shaw (ACIP, WG Chair)
Manufacturer presentation: mRNA-1345 (Moderna) immunogenicity in adults 18-59 at increased risk; 24-month re-vaccination		TBD (Moderna)
Manufacturer presentation: Arexvy (GSK) immunogenicity in adults 18-49 at increased risk; 36-month re-vaccination		TBD (GSK)
Post marketing surveillance: FDA		TBD (FDA)
Economic analysis of adult RSV vaccination		Dr. David Hutton (University of Michigan)
Update to benefits and risk discussion		Dr. David Hutton (University of Michigan)
Comparison of economic analyses of adult RSV vaccination		Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
Evidence to Recommendations		TBD (CDC/NCIRD)
Clinical Considerations		TBD (CDC/NCIRD)
<b>11:30</b>	<b>Break</b>	
<b>11:40 Public Comment</b>		
<b>12:00 VOTES</b>		
<u>RSV Vaccines - Adults</u>		TBD (CDC/NCIRD)
<b>12:25</b>	<b>Break</b>	
<b>12:55 Human Papillomavirus (HPV) Vaccines</b>		
Introduction		Dr. Oliver Brooks (ACIP, WG Chair)
Update on literature related to reduced number of doses for HPV vaccination series		Dr. Carla DeSisto (CDC/NCIRD)
KEN SHE study		Dr. Ruanne Barnabas (Harvard University)
Modeling of reduced number of doses for HPV vaccination series		TBD
Modified EtR: Wording of the age for routine HPV vaccination		Dr. Ruth Stefanos (CDC/NCIRD)
Work Group next steps		Dr. Lauri Markowitz (CDC/NCIRD)
<b>2:55</b>	<b>Break</b>	
<b>3:10 Mpox Vaccine</b>		
Introduction		Dr. Bonnie Maldonado (ACIP, WG Chair)
Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds		Dr. Buddy Creech (Vanderbilt)
EtR for JYNNEOS in outbreaks and due to the 2022 global outbreak		Dr. Faisal Minhaj (CDC/NCEZID)
<b>4:50 Pneumococcal Vaccines</b>		
Workgroup Next Steps and Proposed Work Plan		Dr. Miwako Kobayashi (CDC/NCIRD)
<b>5:05 Lyme Disease Workgroup</b>		Dr. Grace Marx (CDC/NCEZID)
<b>5:10 Recess</b>		

**Friday, February 28, 2025**

**8:00 Welcome & Introductions**

Dr. Keipp Talbot (ACIP Chair)  
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

**8:10 COVID-19 Vaccines**

Introduction  
Moderna mRNA-1283 COVID-19 vaccine  
Epidemiology and risk factors for COVID-19 hospitalizations  
Vaccine effectiveness update  
Work Group Considerations for use of 2025-2026 COVID-19 vaccines

Dr. Robert Schechter (ACIP, WG Chair)  
TBD (Moderna)  
Dr. Fiona Havers (CDC/NCIRD)  
Dr. Ruth Link-Gelles (CDC/NCIRD)  
TBD (CDC/NCIRD)

**10:10** *Break*

**10:25 Cytomegalovirus (CMV) Vaccines**

Introduction  
CMV and cCMV epidemiology and disease burden  
CMV vaccine safety and immunogenicity data  
Initial work group considerations for CMV vaccine policy

Dr. Denise Jamieson (ACIP, WG Chair)  
Dr. Tatiana Lanzieri (CDC/NCIRD)  
Dr. Lori Panther (Moderna)  
Dr. Tatiana Lanzieri (CDC/NCIRD)

**11:25 Adjourn**

***Acronyms***

CDC Centers for Disease Control and Prevention  
CMS Centers for Medicare and Medicaid Services  
CORVD Coronavirus and Other Respiratory Viruses Division  
COVID-19 Coronavirus disease 2019  
EtR Evidence to Recommendations Framework  
FDA Food and Drug Administration  
GRADE Grading of Recommendations Assessment, Development and Evaluation  
HRSA Health Resources and Services Administration  
HPV Human papillomavirus  
IHS Indian Health Service  
ISO Immunization Safety Office  
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention  
NCIRD National Center for Immunization & Respiratory Diseases  
NCEZID National Center for Emerging and Zoonotic Diseases  
NIAID National Institute of Allergy and Infectious Diseases  
OIDP Office of Infectious Disease and HIV/AIDS Policy  
RSV Respiratory Syncytial Virus (RSV)  
SARS-CoV- Severe Acute Respiratory Syndrome Coronavirus 2  
WG Work Group  
WHO World Health Organization  
VAERS Vaccine Adverse Event Reporting System  
VE Vaccine Effectiveness  
VFC Vaccines for Children